Yoshihito Daimon

United Immunity Co. Ltd. is a Japanese company that specializes in pipeline nano technology and immunity fusion technology, specifically in the field of cancer immunotherapy. The company is based in Tsu, Japan and was founded in 2017 by Naozumi Harada, who has been the CEO since then. The company's diverse products, including "nano immunotherapy," have shown promising clinical results and research in the treatment of sex cancer. The company is currently recruiting a researcher in the cancer immunotherapy field to analyze the action mechanism of nanotechnology applied cancer evaluation and drug evaluation using immunological methods. The company's focus is on the development of treatment for the cause of cold tumor type cancer through the understanding of tumor-associated macrophages.